About Nuclein
Nuclein is a company based in Austin (United States) founded in 2017. Nuclein has raised $30.09 million across 7 funding rounds from investors including Trinity Investors. Nuclein offers products and services including DASH Rapid PCR System and DASH SARS-CoV-2 & Flu A/B Test. Nuclein operates in a competitive market with competitors including CellScope, Orphidia, Mel-Mont Medical, ParaSonic and PreDiagnose, among others.
- Headquarter Austin, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nuclein, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$30.09 M (USD)
in 7 rounds
-
Latest Funding Round
$11.11 M (USD), Series B
Jul 23, 2026
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nuclein
Nuclein offers a comprehensive portfolio of products and services, including DASH Rapid PCR System and DASH SARS-CoV-2 & Flu A/B Test.
Delivers lab-quality PCR results in 15 minutes for point-of-care use.
Enables detection of SARS-CoV-2 and influenza viruses via PCR.
People of Nuclein
Unlock access to complete
Funding Insights of Nuclein
Nuclein has successfully raised a total of $30.09M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $11.11 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nuclein
Nuclein has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Trinity Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for Nuclein
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nuclein
Investment portfolio details for Nuclein
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nuclein
Detailed financials for Nuclein
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nuclein Comparisons
Peer comparison for Nuclein
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nuclein
Nuclein operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CellScope, Orphidia, Mel-Mont Medical, ParaSonic and PreDiagnose, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
In-ear visibility is enabled by smartphone-attached otoscope for at-home diagnosis.
|
|
| Locked | Locked | Locked |
Handheld device for point-of-care chronic disease diagnostics is developed.
|
|
| Locked | Locked | Locked |
Molecular screening devices for early infectious disease detection are developed.
|
|
| Locked | Locked | Locked |
Offers a home-use device for effectively eliminating lice and other parasites.
|
|
| Locked | Locked | Locked |
Point-of-care devices for early bacterial infection detection are developed.
|
Detailed competitors of Nuclein
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nuclein
Complete news archive for Nuclein
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nuclein
Nuclein was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Nuclein is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Nuclein is a funded company, having raised a total of $30.09M across 7 funding rounds to date.
Nuclein was founded in 2017 in Austin, United States, and operates in the medical diagnostics sector. A handheld PCR device named NUCLEIN is developed, utilizing standard real-time PCR technology. No technical expertise is required for operation, and the battery-powered unit delivers results within one hour. Applications include diagnosis of COVID-19 and other infectious diseases in field settings.
Nuclein's top competitors include CellScope, Mel-Mont Medical and Orphidia.
Nuclein offers DASH Rapid PCR System and DASH SARS-CoV-2 & Flu A/B Test.
Nuclein has 1 investor. Key investors include Trinity Investors.